News

Registration Now Open for Catalyst Life Sciences Conference

The Virginia Catalyst, also known as the Virginia Biosciences Health Research Corporation (VBHRC), announced that registration is open for the Catalyst Life Sciences Conference. The event will be held October 6-7, 2022 at the Omni Hotel in  Richmond, Virginia.

This conference is designed for scientists, engineers, entrepreneurs, incubators and biohubs, life science companies, technology transfer departments and economic development departments. The format consists of expert panels sharing their knowledge and engaging in dialog with the audience.

Joni L. Rutter, Ph.D. will be a keynote speaker. Dr. Rutter is the Acting Director of the National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH). NCATS was established to transform the translational process so that new treatments and cures for disease can be delivered to patients faster.

Expert panel topics include: Best Practices for Building a High-Potential Company, Scientists and Engineers as Entrepreneurs, Raising Capital, Establishing and Building Ecosystems, Growing Pharmaceutical Manufacturing and R-D Cluster, and Partnering with Companies and Healthcare Systems. For the full agenda and speakers, visit: https://www.virginiacatalyst.org/agenda.html.

“The Virginia Catalyst and our major Virginia-based research universities, along with Virginia Bio are excited to host a major life sciences conference to share best practices and encourage collaborations. It is through this collaborative ecosystem that we are improving human health and further developing our life science economy by creating innovative companies, capital formation, and job creation,” said Michael Grisham, President & CEO, Virginia Catalyst.

To register: https://www.virginiacatalyst.org/registration.html

Recent News

07/17/2025

RIVANNA’s next-generation ultrasound guidance platform and AI-driven imaging software receive FDA 510(K) clearance

RIVANNA®, developers of world-first imaging-based medical technologies, announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) regarding the Accuro® 3S diagnostic ultrasound system and SpineNav-AI™ image processing software. This clearance authorizes the use of both technologies in United States hospital and clinical settings, providing anatomical guidance during needle or

07/15/2025

CEL-SCI Announces Closing of $5.7 Million Offering Priced At-The-Market Under NYSE American Rules

CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a clinical stage cancer immunotherapy company, announced the closing of its best-efforts offering of 1,500,000 shares of its common stock. Each share of common stock was sold at an offering price of $3.82 per share, priced at-the-market under NYSE American rules. Total gross proceeds from the

07/15/2025

Civica Appoints Dave Sehgal as Chief Manufacturing Officer and Supply Chain Officer

Civica announced the appointment of Dave Sehgal, Ph.D. as its new Chief Manufacturing Officer and Supply Chain Officer, effective July 21. In this role, Dr. Sehgal will lead Civica’s manufacturing strategy and operations, reporting directly to Ned McCoy, President and CEO. “We are excited to welcome Dave to our leadership team,” said McCoy. “His deep